Using fecal immunochemical test values below conventional cut-off to individualize colorectal cancer screening

Abstract

Background and study aims Of the participants in the Danish screening program, 89.9 % to 92.5 % have fecal immunochemical test (FIT) values < 10 μg/g feces (equivalent to 50 ng hemoglobin/mL buffer). This study aimed to investigate the risk of interval colorectal cancer (CRC) in this group before the next biennial screening round.

Patients and methods This cohort study included all citizens from the region of Southern Denmark who participated in the Danish bowel screening program from 2014 trough 2016 and had a FIT value < 10 μg/g feces. Individuals receiving a CRC diagnosis were identified through the national CRC registry, with a follow up of 2 years corresponding to the current screening interval. We also examined the 3-year CRC incidence. Hazard ratios (HRs) were estimated using univariate and multivariate Cox proportional hazard regression models.

Results Data from 185,654 citizens presenting with a FIT value < 10 μg/g feces were eligible for analysis. Overall, interval CRC incidence was 0.07 % within 2 years with HRs of 4.16 (95 % confidence interval [CI] 2.67;6.48) and 5.8 (95 % CI 3.34;10.05) for FIT values of 4 to 6.9 μg/g feces and 7 to 9.9 μg/g feces, respectively, compared to those having a FIT value below the limit of quantification of 4 μg/g feces. After 3 years, the overall CRC incidence increased to 0.14 %; however, this was not significant.

Conclusions This study demonstrates a positive correlation between FIT value and risk of interval cancer even for very low values. It further suggests that an increase in the screening interval could be reasonable in the low FIT categories.

Publication History

Received: 24 June 2021

Accepted after revision: 03 December 2021

Article published online:
14 April 2022

• References

• 1 Danish Health Authority. Recommendations in realtions to screening for colorectal cancer. Available from: https://www.sst.dk/da/udgivelser/2012/~/media/1327A2433DDD454C86D031D50FE6D9D6.ashx
• 2 Kronborg O, Fenger C, Olsen J. et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471
• 3 Hardcastle JD, Chamberlain JO, Robinson MH. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477
• 4 Danish Health Authority. Colorectal cancer screening. The significance of the particatipation rate – a medical technology assesment. Available from: https://www.sst.dk/~/media/CE2CCF697AA14759909EA5DEEA9FBFC1.ashx
• 5 Danish Colorectal Cancer Screening Database. 2016 yearly report from the Danish Colorectal Cancer Screening Database. Available from: https://www.sundhed.dk/content/cms/45/61245_dts%C3%A5rsrapport-2016_offentlig-version.pdf
• 6 Danish Colorectal Cancer Screening Database. 2017 yearly report from the Danish Colorectal Cancer Screening Database. Available from: https://www.sundhed.dk/content/cms/45/61245_dts%C3%A5rsrapport-2016_offentlig-version.pdf
• 7 Danish Colorectal Cancer Screening Database. 2018 yearly report from the Danish Colorectal Cancer Screening Database. Available from: https://www.sundhed.dk/content/cms/45/61245_aarsrapport2018_anonymiseret_endelig_marts2020_2.pdf
• 8 Ingeholm P, Gögenur I, Iversen LH. Danish Colorectal Cancer Group Database. Clin Epidemiol 2016; 8: 465-468
• 9 Zorzi M, Hassan C, Senore C. et al. Interval colorectal cancers after negative faecal immunochemical test in a 13-year screening programme. J Med Screen 2021; 28: 131-139
• 10 Chen LS, Yen AM, Chiu SY. et al. Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort. Lancet Oncol 2011; 12: 551-558
• 11 Krøijer R, Baatrup G. Great variations of interval cancer rate (ICR) in colorectal cancer screening subgroups. In: European Society of Coloproctology. Vienna. 2019
• 12 Toes-Zoutendijk E, Kooyker AI, Dekker E. et al. Incidence of interval colorectal cancer after negative results from first-round fecal immunochemical screening tests, by cutoff value and participant sex and age. Clin Gastroenterol Hepatol 2020; 18: 1493-1500
• 13 Digby J, Fraser CG, Carey FA. et al. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round. J Med Screen 2017; 24: 62-68
• 14 Larsen MB, Njor S, Ingeholm P. et al. Effectiveness of colorectal cancer screening in detecting earlier-stage disease-a nationwide cohort study in Denmark. Gastroenterology 2018; 155: 99-106
• 15 Cardoso R, Guo F, Heisser T. et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol 2021; 22: 1002-1013
• 16 Njor SH, Andersen B, Friis-Hansen L. et al. The optimal cut-off value in fit-based colorectal cancer screening: An observational study. Cancer Med 2021; 10: 1872-1879
• 17 Sarkeala T, Färkkilä M, Anttila A. et al. Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland. BMJ Open 2021; 11: e046667
• 18 Ribbing Wilén H, Blom J, Höijer J. et al. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives. Scand J Gastroenterol 2019; 54: 303-310
• 19 O'Reilly SM, MacNally S, O'Donoghue D. et al. Correlation of fecal immunochemical testing levels with pathology results in a national colorectal cancer screening program. Clin Transl Gastroenterol 2021; 12: e00277